metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Efficacy and safety of treatment with terlipressin infusion vs. bolus in gastroi...
Información de la revista
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Open Access
Efficacy and safety of treatment with terlipressin infusion vs. bolus in gastrointestinal bleeding of variceal origin in a third-level hospital
Visitas
272
N Moreno Aguilar, DE Meléndez Mena, MA Mendoza Torres
UMAE. Puebla Specialty Hospital. IMSS. Mexico
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Vol. 27. Núm S3

Abstracts from XVII Mexican Congress of Hepatology

Más datos
Introduction and Objectives

Digestive bleeding of variceal origin represents an event with high mortality and pharmacological treatment is the mainstay in its management. In our setting, bolus terlipressin is the available treatment, although with frequent adverse effects, so we compared the efficacy and safety of bolus terlipressin vs. infusion for variceal bleeding.

Materials and methods

Experimental, randomized and comparative study in which adult patients from the Hospital de Especialidades Puebla were included from March 1, 2021, to October 31, 2021, with portal hypertension who presented with upper gastrointestinal bleeding of variceal origin and were administered terlipressin in infusion and in boluses. The protocol was approved by the local ethics committee and all patients participated with informed consent. Statistical analysis was performed in the IBM SPSS v. 28.

Results

14 patients were randomly admitted, 7 to the infusion group and 7 to the bolus group. There were significant differences in the variables (Table 1) of days of hospital stay (p=0.023), adverse effects (p=0.018) and drug requirement (p=0.001); in the rest of the variables, there were no significant differences. Table 1.

Conclusions

Given the size of our sample and study design, larger studies with better statistical power are needed to corroborate our results.

Funding

The resources used in this study were from the hospital without any additional financing

Declaration of interest

The authors declare no potential conflicts of interest.

Texto completo

Table 1. Comparative table of results of the study variables between the control group (bolus) and the experimental group (infusion)

Study variables  Bolus (n=7)  Infusion (n=7)  P Value (CI 95%)  Correlation  RR 
Treatment failure  0 (0.0%)  0 (0.0%)  NA  NA  NA 
Adverse effects  4 (57%)  0 (0.0%)  0.018  5.60  3.33 (1.2-8.5) 
Requirement of red cell concentrates  1 (0-2)  0.86 (0-3)  0.196  0.311  NA 
Days of hospital stay  3.643 (3-5)  3.171 (3-3.5)  0.023  1.590  NA 
Rebleeding at 6 weeks  0 (0.0%)  0 (0.0%)  NA  NA 
Drug requirement  22.29  12.14  0.001  0.0  NA 

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos